13 January 2020 in PLOS ONE
Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective treatments to enhance the clinical response rate. One potential therapeutic target is survivin, a protein that is normally expressed during embryonic and fetal development and has a critical impact on cell cycle control and apoptosis. In adulthood, survivin is not present in most normal adult cells, but is significantly re-expressed in tumor tissues. In PDAC, elevated survivin expression is correlated with treatment resistance and lower patient survival, although the underlying mechanisms of survivin’s action in this type of cancer is poorly understood. Using patient derived xenografts of PDAC and their corresponding primary pancreatic cancer lines (PPCL-46 and PPCL-LM1) possessing increased expression of survivin, we aimed to evaluate the therapeutic response of a novel survivin inhibitor, UFSHR, with respect to survivin expression and the tumorigenic characteristics of PDAC. Cell viability and apoptosis analyses revealed that repressing survivin expression by UFSHR or YM155, a well-known inhibitor of survivin, in PPCLs effectively reduces cell proliferation by inducing apoptosis. Tumor cell migration was also hindered following treatment with YM155 and UFSHR. In addition, both survivin inhibitors, particularly UFSHR, effectively reduced progression of PPCL-46 and PPCL-LM1 tumors, when compared to the untreated cohort. Overall, this study provides solid evidence to support the critical role of survivin in PDAC progression and proposes a novel survivin inhibitor UFSHR that can become an alternative strategy for this type of cancer.
12 January 2024 in Nature Reviews Immunology
1 September 2020 in Nature Reviews Immunology
8 December 2025 in Research Square
Colorectal cancer (CRC) accounts for 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. Immunotherapies have significantly advanced over the past decades, marking a major breakthrough in cancer treatment. While anti-PD-1 therapy is utilized in both local and advanced disease, up to 50% of mismatch repair deficient (MMRd) and most mismatch repair proficient (MMRp) CRC fail to respond. Using orthotopic animal and patient-derived models of CRC, along with single cell and spatial analyses, we determined that colocalization and interactions between MHC + C1Q + CXCL9 + macrophages and TCF + PRF1 + T cell subsets are associated with control of tumor growth during anti-PD-1 treatment. In contrast, resistance is associated with upregulation of TIM3, LAG3, TIGIT, and PD-1 expression on T cells, and tumor infiltration by immunosuppressive TREM2 + macrophages and monocytes in T cell excluded zones. A novel combinatorial checkpoint blockade targeting TREM2, LAG3, CTLA4, and PD-1 achieves up to 100% tumor clearance in MMRd CRC and > 70% in MMRp CRC models, compared to 0% with anti-PD-1 monotherapy. This approach induces durable anti-tumor immune memory, mediated by coordinated interactions among MHC + macrophages, CD4+/CD8 + T cells, and TCF + T cells. It also reduced infiltration by immunosuppressive myeloid cells and T cell exhaustion. Together this study identifies key T cell and macrophage subsets mediating the efficacy of immunotherapy in overcoming immune escape in both MMRd and MMRp CRC settings.